Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb;41(1):110-25.
doi: 10.1053/j.seminoncol.2013.12.006. Epub 2013 Dec 12.

Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor

Eamon M Berge  1 , Robert C Doebele  2
Affiliations
Review

Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor

Eamon M Berge et al. Semin Oncol. 2014 Feb.

Abstract

The diagnostic testing, treatment and prognosis of non-small cell lung cancer (NSCLC) has undergone a paradigm shift since the discovery of sensitizing mutations in the epidermal growth factor receptor (EGFR) gene in a subset of NSCLC patients. Several additional oncogenic mutations, including gene fusions and amplifications, have since been discovered, with a number of drugs that target each specific oncogene. This review focuses on oncogenes in NSCLC other than EGFR and their companion "targeted therapies." Particular emphasis is placed on the role of ALK, ROS1, RET, MET, BRAF, and HER2 in NSCLC.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURES:

Eamon Berge: no financial conflicts of interest to disclose.

Robert C. Doebele: Advisory board for Pfizer and Boehringer Ingelheim, research grants from Pfizer, Eli Lilly and ImClone, patent filed with USPTO for NTRK1 as a predictive biomarker.

Figures

Figure 1
Figure 1
Graphic representations of targeted therapy in Non-small cell lung cancer (NSCLC). Approximate representation of Food and Drug Administration (FDA) approved targeted therapies and therapies in development in NSCLC with approximate percentages of targetable oncogenes in adenocarcinoma and squamous cell carcinoma of the lung.
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. - PubMed
    1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907. - PubMed
    1. Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) Available from URL: http://seer.cancer.gov/csr/1975_2009_pops09/
    1. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14. - PubMed
    1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50. - PubMed

MeSH terms